Last reviewed · How we verify

NAI + Nivolumab + Ipilimumab

ImmunityBio, Inc. · Phase 3 active Small molecule

This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab).

This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab). Used for Metastatic melanoma, Advanced renal cell carcinoma, Other solid tumors (Phase 3 evaluation).

At a glance

Generic nameNAI + Nivolumab + Ipilimumab
SponsorImmunityBio, Inc.
Drug classCheckpoint inhibitor combination with NK cell activator
TargetPD-1, CTLA-4, and NK cell activation pathways
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

NAI (a natural killer cell activator) primes innate immune responses, while Nivolumab and Ipilimumab are checkpoint inhibitors that remove brakes on T-cell and immune activation. Together, they work synergistically to enhance both innate and adaptive anti-tumor immunity through complementary mechanisms of immune checkpoint blockade and NK cell activation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: